J&J Stock Dips After $10 Billion Settlement Dismissed by Judge

Johnson & Johnson (NYSE: JNJ) experienced a notable drop in its stock value following a legal setback involving its talc products. The company faced a significant legal hurdle when a U.S. bankruptcy judge dismissed its $10 billion settlement proposal. This settlement was intended to resolve numerous lawsuits alleging that J&J’s talc products are linked to ovarian cancer.

Legal Setback for Johnson & Johnson as Judge Dismisses Settlement Proposal

This marks the third unsuccessful attempt by the company to navigate these claims through bankruptcy court. As a result, J&J plans to address these claims within the tort system, choosing not to appeal the recent ruling. The impact of this decision was immediately reflected in the stock market, with J&J shares declining by over 3%, trading at $160.08 in premarket.

Join our Telegram group and never miss a breaking digital asset story.

JNJ Stock Brief

Over the past 52 weeks, J&J’s stock has ranged from a low of $140.68 to a high of $169.99. Despite the current challenges, the market analysts maintain a “Buy” recommendation for J&J, with a target mean price of $169.065, suggesting confidence in the company’s long-term prospects.

Key financial metrics such as a dividend yield of 2.99% and a trailing P/E ratio of 28.64 further underscore the company’s robust market position.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.